Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gw493838. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 10/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.66 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw493838 SCHEMBL6935807 | 1.00 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BPRMT5 | |
| Gw493838 SCHEMBL29384676 | 1.00 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BPRMT5 | |
| Gw493838 SCHEMBL6250937 | 1.00 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BPRMT5 | |
| Gw493838 SCHEMBL6225102 | 1.00 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BPRMT5 | |
| Gw493838 SCHEMBL7192949 | 0.93 | ADORA3 (0.60) | ADORA3ADORA1ADORA2AADORA2BPRMT5 | |
| SCHEMBL6574202 | 0.90 | ADORA3 (0.52) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL6576757 | 0.90 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL6574679 | 0.90 | ADORA3 (0.53) | ADORA3ADORA1ADORA2AADORA2BPRMT5 | |
| SCHEMBL6572751 | 0.90 | ADORA3 (0.71) | ADORA3ADORA1ADORA2AADORA2BPRMT5 | |
| SCHEMBL6575135 | 0.88 | ADORA3 (0.66) | ADORA3ADORA1ADORA2AADORA2BPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180908-A1 | Adenosine derivative in polymorph ii form | GLAXO GROUP LIMITED (GB) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180908-A1 | Adenosine derivative in polymorph ii form | ADORA2A, NT5C2, AMPD2 | ADORA1 42/4885ADORA3 6/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.